Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses

Pediatric Infectious Disease Journal

Volumn 29, Issue 3, 2010, Pages 263-265

  Goveia, Michelle G ^a   Suprun, Leora ^a   Itzler, Robbin F ^a   McFetridge, Richard ^a   Dallas, Michael J ^a   Kuter, Barbara J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Dosing window; Pentavalent rotavirus vaccine; RotaTeq; Rotavirus

Indexed keywords

PENTAVALENT HUMAN BOVINE REASSORTANT ROTAVIRUS VACCINE; PLACEBO; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BRONCHIOLITIS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GASTROENTERITIS; HEALTH CARE UTILIZATION; HUMAN; PRIORITY JOURNAL; TREATMENT DURATION; VACCINATION;

EID: 77649195111     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181be6257     Document Type: Article

References (8)

1. Glass RI, Parashar UD, Bresee JS, et al. Rotavirus vacines: current prospects and future challenges. Lancet. 2006;368:323-332.
2. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infecious Diseases/European Society for Paediatric Gastroenter-ology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr. 2008; 46(suppl 2):S38-S48
3. Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children. MMWR Morb Mortal Wkly Rep. 2006;55(RR-12):1-13.
4. Food and Drug Administration. Product approval information-licensing action, package insert: RotaTeq (Rotavirus Vaccine, Live, Oral, Pentava-lent), Merck. Rockville, MD. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, February 2006.
5. Block SL, Vesikari T, Goveia MG, et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics. 2007;119(1):11-18.
6. Vesikari T, Karvonen A, Allen S, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq, against hospitalizations and emergency department visits through the third year of life: The Finnish Extension Study. In: International Congress of Infectious Diseases; June 19-22, 2008; Kuala Lumpur, Malaysia. Abstract 19.025.
7. Dennehy PH, Goveia MG, Dallas MJ, et al. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. Int J Infect Dis. 2007;11:S36-S42.
8. Haber P, Manish P, Hua W, et al. Monitoring intussusception following RotaTeq vaccination: Data from the US Vaccine Adverse Event Reporting System. In: 48th Annual Interscience Conference on Antimicrobial